NYSE:PRGOPharmaceuticals
The Bull Case For Perrigo (PRGO) Could Change Following ITC Probe Of Lidocaine Patch Patents
On April 14, 2026, the U.S. International Trade Commission opened a Section 337 investigation into whether imported over-the-counter topical lidocaine patches sold by Perrigo and several peers infringe specific J.A.R Laboratories patent claims, which could lead to exclusion or cease-and-desist orders affecting U.S. sales.
This enforcement action brings Perrigo’s role in the U.S. lidocaine patch market under regulatory scrutiny, raising questions about potential impacts on its...